Therapeutic Antibodies

BMI’s technology is able to alter the natural antigenicity and immunogenicity of targeted protein antigens for vaccine purposes. The strength of the technology, however, is that the very same antigens/immunogens used for vaccine purposes can also be use to induce and select for unique monoclonal antibodies for therapeutic, diagnostic, and research purposes. Identification of novel therapeutic antibodies using Immune Dampening and Refocusing can be done in infectious disease and oncology applications.